Abstract:There has been an increased interest in pharmacokinetics and pharmacodynamics (PKPD) of anti-tuberculosis drugs. A better understanding of the relationship between drug exposure, antimicrobial kill and acquired drug resistance is essential not only to optimize current treatment regimens but also to design appropriately dosed regimens with new anti-tuberculosis drugs. Although the interest in PKPD has resulted in an increased number of studies, the actual bench-to-bedside translation is somewhat limited. One of the reasons could be differences in methodologies and outcome assessments that makes it difficult to compare the studies. In this paper we summarize most relevant in vitro , in vivo , in silico and human PKPD studies performed to optimize the drug dose and regimens for treatment of tuberculosis. The in vitro assessment focuses on MIC determination, static time-kill kinetics, and dynamic hollow fibre infection models to investigate acquisition of resistance and killing of Mycobacterium tuberculosis populations in various metabolic states. The in vivo assessment focuses on the various animal models, routes of infection, PK at the site of infection, PD read-outs, biomarkers and differences in treatment outcome evaluation (relapse and death). For human PKPD we focus on early bactericidal activity studies and inclusion of PK and therapeutic drug monitoring in clinical trials. Modelling and simulation approaches that are used to evaluate and link the different data types will be discussed. We also describe the concept of different studies, study design, importance of uniform reporting including microbiological and clinical outcome assessments, and modelling approaches. We aim to encourage researchers to consider methods of assessing and reporting PKPD of anti-tuberculosis drugs when designing studies. This will improve appropriate comparison between studies and accelerate the progress in the field.

Overview the PK/PD research methods of anti-anaerobic drugs

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Antibacterial Pharmacokinetics/pharmacodynamics and Optimizing Treatment of Nosocomial Pneumonia

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials

Application of PK/PD Parameters in Selection of Antibiotic Regimes for Patients with Multi-Drug Resistant Bacterial Infection

Advances in PK/PD studies of antifungals

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models

Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases.

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction

Optimizing the anti-infection therapy by the PK/PD theory

Promising treatments for refractory pneumonia caused by multidrug-resistant Klebsiella pneumoniae

Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer's Perspective

The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal.

Population pharmacokinetics of antibacterial agents in the older population: a literature review

Advances in the Study of the Microbial Efflux Pumps and Its Inhibitors Development

Research progress on resistance of predominant periodontal anaerobes

Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves

An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients

Research progress on the effect of antibiotics on anaerobic fermentation gas production and microorganisms of animal manure